scholarly journals Prognostic significance of preoperative serum inflammation markers in patients with male breast cancer

2021 ◽  
Author(s):  
Xing Li ◽  
Zhengchong Xiong ◽  
Jin Wang ◽  
Juan Fu ◽  
Xinhua Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Male Breast ◽  
Cancer Center ◽  
Breast Cancer Patients ◽  
Inflammation Markers ◽  
Lymphocyte Ratio

Abstract BackgroundThere were no predictive prognosis factors of serum in male breast cancer, while breast cancer is a heterogeneous disease. The purpose of our study was to determine the prognostic implications of the pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) in the serum of patients with male breast cancer. Methods：We retrospectively identified an random cohort of male breast cancer patients treated at the Sun Yat-Sen University Cancer Center between Jan1, 1996 and Dec31, 2016. A number of 108 patients had a different inflammation markers recorded pre-operation. Survival status was retrieved from our cancer center registry and phone follow-up. Cox proportional hazards regression model were used to analyze the disease-free survival (DFS) and overall survival (OS). Results：Among these patients in this study, 13 (12%) had disease recurrence, and 7 (6.5%) patients appeared distant metastasis. No statistically significant association of the preoperative NLR, PLR or LMR level with patients’ different outcomes was found. Conclusions: In short, we were unable to establish a connection between preoperative inflammation biomarkers and male breast cancer patients’ survival. Neither NLR, PLR nor LMR is useful for predicting prognosis in male breast cancer patients, and prospective studies to evaluate the above biomarkers as a simple prognostic trail is necessary.

scholarly journals Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients

2019 ◽  
Vol 30 ◽  
pp. v774-v775
Author(s):  
J. Huszno ◽  
Z. Kolosza ◽  
J. Mrochem-Kwarciak ◽  
A. Zajusz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Prognostic Value ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Lymphocyte Ratio

BRCA gene mutations in Slovenian male breast cancer patients

2007 ◽  
Vol 4 (03) ◽  
Author(s):  
N Besic ◽  
B Cernivc ◽  
J De Greve ◽  
K Lokar ◽  
M Krajc ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Gene Mutations ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Brca Gene

scholarly journals The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Tumour Size ◽  
Male Breast ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Chemotherapy Group

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

Abstract 2697: Prognostic significance of intratumoral neutrophil lymphocyte ratio (NLR) in breast cancer patients

2021 ◽  
Author(s):  
Yoshihisa Tokumaru ◽  
Masanori Oshi ◽  
Vijayashree V. Murthy ◽  
Eriko Katsuta ◽  
Nobuhisa Matsuhashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Breast Cancer Patients ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

scholarly journals Mediating Effects of Patients’ Stigma and Self-Efficacy on Relationships Between Doctors’ Empathy Abilities and Patients’ Cellular Immunity in Male Breast Cancer Patients

2018 ◽  
Vol 24 ◽  
pp. 3978-3986 ◽  
Author(s):  
Ningxi Yang ◽  
Yingnan Cao ◽  
Xiaoyan Li ◽  
Shiyue Li ◽  
Hong Yan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Cellular Immunity ◽  
Self Efficacy ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Mediating Effects

scholarly journals Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients

2011 ◽  
Vol 33 (1) ◽  
pp. 17-26 ◽  
Author(s):  
Samuel F. Gilbert ◽  
Amr S. Soliman ◽  
Mehdi Karkouri ◽  
Meaghen Quinlan-Davidson ◽  
Ashley Strahley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Cag Repeat ◽  
Clinical Profile ◽  
Breast Cancer Patients ◽  
Repeat Region

Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients

2015 ◽  
Vol 152 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Andreas D. Hartkopf ◽  
Florin-Andrei Taran ◽  
Christina B. Walter ◽  
Markus Hahn ◽  
Tanja Fehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Male Breast Cancer ◽  
Early Stage ◽  
Disseminated Tumor Cells ◽  
Male Breast ◽  
Breast Cancer Patients

Surgical management of male breast cancer patients referred to the national cancer institute: University of Gezira; the forgotten lesson

2014 ◽  
Vol 9 (1) ◽  
pp. 11
Author(s):  
AhmedM Elhaj ◽  
AlgaylaniA Eltayeb ◽  
DafallaO Abuidris ◽  
AhmedA Alshaikh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Surgical Management ◽  
Male Breast Cancer ◽  
National Cancer Institute ◽  
Male Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document